Hawaii Cannabis Software

How Hawaii Regulates Cannabis Licenses

Hawaii holds a notable distinction in the history of cannabis policy in the United States: it was the first state to legalize medical cannabis through an act of the legislature, rather than through a voter initiative. That happened in 2000, when Act 228 the Medical Cannabis Registry Program was signed into law, allowing qualifying patients and their caregivers to cultivate cannabis for personal medical use. However, it took another 15 years before the state established a licensed commercial dispensary system. In 2015, Act 241 was signed into law and codified as Chapter 329D of the Hawaii Revised Statutes (HRS), creating the framework for commercial cannabis production, manufacturing, and retail dispensing that governs the industry today.

Recreational cannabis remains illegal in Hawaii as of 2026. Despite recurring legislative efforts including adult-use bills introduced in the 2025 session none have passed. As of January 21, 2026, companion bills HB 1624 and SB 2420 were introduced to place an adult-use legalization question on the November 2026 ballot, but no legislative action has yet been finalized. Operators and investors should monitor the Hawaii Legislature's 2026 session for any changes, as a successful ballot measure could open a new licensing framework as early as 2027.

The regulatory body overseeing Hawaii's cannabis dispensary licensing program is the Office of Medical Cannabis Control and Regulation (OMCCR), which operates under the Hawaii State Department of Health (HDOH). The OMCCR is responsible for dispensary licensure, compliance inspections, laboratory oversight, and enforcement of state law under Chapter 329D, HRS and the administrative rules codified in Chapter 11-850 of the Hawaii Administrative Rules (HAR), which were updated under new interim rules effective November 17, 2025. Operators must be familiar with both the statute and the current interim rules, as the HAR governs day-to-day operational compliance including packaging, labeling, testing, and security requirements.

The patient-facing side of the program the Medical Cannabis Registry is governed separately under Chapter 329, HRS Part IX and administered by the same HDOH office. Patients must hold an active 329 Registration Card issued by the Department of Health to legally purchase from licensed dispensaries. As of September 30, 2025, Hawaii's Medical Cannabis Registry has grown significantly, supporting a network of 8 licensed dispensary operators with facilities across all four counties statewide.

Medical Cannabis Dispensary License

The Medical Cannabis Dispensary License is the sole commercial cannabis business license issued in Hawaii under Chapter 329D, HRS. It is a vertically integrated license meaning a single licensee is authorized to cultivate, manufacture, and retail cannabis products all under one license. There is no separate cultivation-only, manufacturing-only, or retail-only license type in Hawaii's medical cannabis framework. Every licensed operator in Hawaii is responsible for managing their own supply chain from production through point of sale.

Under the statutory definition in Chapter 329D, HRS, a dispensary licensee may own, operate, or subcontract no more than three production centers and operate up to two retail dispensing locations. Production centers are where cultivation and manufacturing take place. For security reasons, the physical locations of production centers are not publicly disclosed by the HDOH. All cultivation must occur in an enclosed indoor facility defined under Chapter 329D, HRS as a permanent, stationary structure with a solid floor, rigid exterior walls that encircle the entire structure on all sides, and a roof. Notably, the statute provides that for production centers where a license application was submitted after January 29, 2016, the roof may be partially or completely transparent or translucent, allowing for greenhouse-style operations.

Hawaii issued exactly eight dispensary licenses statewide two to operators in the City and County of Honolulu, two in Hawaii County, two in Maui County, and two in Kauai County. Applications were accepted from January 12 through January 29, 2016, and the eight licensees were announced on April 29, 2016. The HDOH is not currently accepting new dispensary license applications until further notice. This means Hawaii's commercial cannabis market is fully closed to new entrants under the current medical framework. As of December 10, 2024, there are 38 operational licensed medical cannabis facilities statewide 13 production centers and 25 retail locations all operated by the original eight licensees and their approved subcontractors.

The application fee for a dispensary license is $5,000, nonrefundable. Applicants were required to demonstrate financial resources of at least $1,000,000 plus a minimum of $100,000 for each retail dispensing location they intended to operate. Applications that did not meet the minimum financial threshold at the time of verification were rejected outright. Owners and principals must be at least 21 years of age with no disqualifying criminal history under Chapter 329D, HRS.

One compliance detail operators must internalize: Act 241 SLH 2025 signed into law during the 2025 legislative session authorized licensed dispensaries to sell hemp products and accessories at retail dispensing locations, effective July 1, 2025. However, the same act explicitly prohibits the sale of hemp products in waiting rooms. This distinction hemp products permitted in retail areas but not in waiting rooms is a specific compliance line that dispensary operators must build into their store layout and operations protocols. Violations related to packaging, labeling, and product placement have historically been among the most common compliance issues cited by OMCCR surveyors during inspections.

Patient Home Cultivation

Hawaii's cannabis framework includes a patient cultivation pathway that operates entirely outside of the commercial dispensary licensing system. Under Chapter 329, HRS, registered patients and their primary caregivers are authorized to cultivate cannabis for personal medical use. As of changes enacted in 2025, primary caregivers may now cultivate for up to five qualifying patients an expansion from the previous limit of one patient. Each cultivation location used by a caregiver may serve no more than five qualifying patients. Patients registered under Chapter 329 may possess an adequate supply, defined as up to four ounces of usable cannabis and up to seven plants regardless of maturity stage.

This patient cultivation right is a meaningful aspect of Hawaii's program because it creates a parallel access pathway outside the commercial dispensary network particularly relevant for patients on neighbor islands with limited dispensary access. Operators and dispensary staff should be aware that patients who also cultivate at home are permitted to do so legally, and that possession of cultivation-sourced cannabis does not require a dispensary transaction.

Out-of-State Patient Access

Hawaii is one of a small number of states that allows qualifying patients from other states to purchase cannabis at licensed dispensaries through a formal reciprocity program. Out-of-state patients who hold a valid medical cannabis registration card from their home state may apply for a Hawaii out-of-state registry card, which permits them to purchase from licensed Hawaii dispensaries during their visit. This program has particular significance given Hawaii's position as a major tourism destination.

A critical compliance gotcha for both patients and dispensary staff: inter-island transport of cannabis is prohibited except in very limited circumstances such as laboratory testing between licensed facilities. Patients registered on one island cannot legally fly their cannabis to another island even within Hawaii because airports are federal property, and transportation of cannabis through federal facilities violates federal law. Patients traveling between islands must purchase cannabis separately on each island they visit. Dispensary staff should be prepared to inform out-of-state and inter-island visitors of this limitation at the point of sale.

Seed-to-Sale Tracking in Hawaii

Hawaii uses BioTrack THC as its state-mandated seed-to-sale tracking system. All licensed dispensaries including their production centers and retail locations are required to track cannabis plants and products through BioTrack from cultivation through retail sale. The HDOH's OMCCR references BioTrack THC as the electronic seed-to-sale tracking system in its annual reporting to the Hawaii State Legislature, confirming it as the operational compliance platform for all licensees.

All cannabis products sold in Hawaii must be tested by a laboratory approved by the OMCCR before reaching retail. The HDOH oversees statewide testing laboratory compliance as part of its broader regulatory mandate under Chapter 329D, HRS. Testing requirements cover safety, potency, and product quality, and labeling requirements are governed by Chapter 11-850, HAR. The updated interim rules effective November 17, 2025 reflect the most current labeling and packaging standards compliance with the updated HAR, not prior versions, is what OMCCR surveyors evaluate during inspections.

Taxes and Financial Considerations

Hawaii does not impose a cannabis-specific excise tax at the state level. Instead, licensed cannabis dispensaries are subject to Hawaii's General Excise Tax (GET), which applies to business activity statewide across all industries. The GET is a privilege tax on the gross income of businesses operating in Hawaii, and unlike a sales tax, it is the business not the consumer that is legally responsible for paying it. Cannabis dispensaries should account for GET obligations as a baseline financial compliance requirement separate from federal tax considerations under IRS Section 280E, which continues to affect federally controlled substance businesses regardless of state law.

2026 Legislative Landscape

Hawaii's cannabis regulatory environment is in an active period of legislative attention. Beyond the adult-use ballot measure proposals introduced in January 2026, the 2025 legislative session produced two significant changes already in effect. Act 241 SLH 2025 expanded the program by authorizing telemedicine for physician certifications meaning patients no longer need in-person visits to obtain or renew their 329 card certification and authorized hemp product sales at dispensary retail locations as noted above. Act 046 SLH 2025 gave OMCCR new authority to impose penalties and take enforcement actions for violations of medical cannabis law, which represents a meaningful expansion of the agency's enforcement toolkit.

For any operator currently holding a Hawaii dispensary license, or any investor monitoring the Hawaii market in anticipation of potential adult-use legalization, the key regulatory documents to track are Chapter 329D, HRS, Chapter 11-850, HAR, and official HDOH OMCCR advisories. The interim rules adopted in late 2024 and updated in November 2025 remain operative and are the compliance standard against which all inspections are conducted. Any changes to the statutory framework resulting from the 2026 legislative session will be reflected in subsequent HDOH administrative rulemaking.